Standout Papers

Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067... 2018 2026 2020 2023 988
  1. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial (2018)
    F. Stephen Hodi, Vanna Chiarion‐Sileni et al. The Lancet Oncology

Immediate Impact

5 by Nobel laureates 10 from Science/Nature 83 standout
Sub-graph 1 of 20

Citing Papers

Renal Cell Carcinoma
2024 Standout
Cutaneous melanoma
2023 Standout
18 intermediate papers

Works of René González being referenced

Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 Trial
2019
Efficacy and safety of nivolumab (NIVO) plus ipilimumab (IPI) in patients with melanoma (MEL) metastatic to the brain: Results of the phase II study CheckMate 204.
2017
and 15 more

Author Peers

Author Last Decade Papers Cites
René González 6499 4272 2587 188 9.0k
Helen Gogas 6319 3737 2158 326 8.9k
Sanjiv S. Agarwala 6012 4167 2440 205 9.5k
Anna C. Pavlick 5666 4641 2166 216 8.7k
Paola Queirolo 5242 2947 2450 229 7.1k
Karl D. Lewis 4782 3882 1440 173 7.6k
Gerald P. Linette 5441 3598 3564 123 9.0k
Jacob Schachter 6291 2924 2908 184 8.2k
Alan Spatz 4627 3344 1776 196 7.5k
Alessandro Testori 5922 3523 2560 212 9.3k
Ana Arance 6070 3995 2032 176 8.2k

All Works

Loading papers...

Rankless by CCL
2026